A carregar...
Publicação
Controlled activation modulates T-cell expansion and phenotype in stirred-tank bioreactors
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.39 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Background aims: Autologous cell therapies using chimeric antigen receptor (CAR) T cells have shown significant clinical success in hematologic cancers. However, current production platforms face challenges in scaling up to produce sufficient numbers of cells to meet the demands of multi-dose regimens. Additionally, tight control over critical process parameters during the distinct stages of cell production is required to maximize key phenotypic characteristics of CAR T-cell products that correlate with improved clinical responses. To address these issues, we propose an integrated manufacturing process in stirred-tank bioreactors (STBs) for controlled T-cell activation and expansion. Methods: By tailoring the stirring profile of STBs (Ambr® 15 bioreactors; Sartorius, Göttingen, Germany), microbeads functionalized with anti-CD3/CD28 antibodies allow control over the initiation/termination of T-cell activation without requiring additional washing steps to remove the activation signaling cues. Results: This strategy resulted in up to a 10-fold increase in T-cell numbers compared with conventional static culture systems, resulting in a final cell concentration of 2.5 × 107 cells/mL after 10 days of culture. Importantly, a higher proportion of CD8+ T cells and lower expression of exhaustion markers programmed cell death protein 1, lymphocyte activation gene 3 and T-cell immunoglobulin and mucin domain 3 (<8%) were obtained in STBs relative to static cultures. Additionally, the anti-CD3/CD28-functionalized microbeads were as efficient as the standard TransAct™ (Miltenyi Biotec, Bergisch Gladbach, Germany) stimuli in activating and expanding T cells in STBs. Conclusions: Overall, this approach presents a promising strategy for the scalable and tightly controlled manufacturing of T-cell therapies, particularly focusing on the T-cell activation step while minimizing manual operations, thus contributing towards more effective and cost-efficient immunotherapies.
Descrição
Funding Information: This work was supported by Funda\u00E7\u00E3o para a Ci\u00EAncia e a Tecnologia (FCT) through the CARTool project ( https://doi.org/10.54499/2022.07312.PTDC ). This work was also funded by FCT/Minist\u00E9rio da Ci\u00EAncia, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health ( UIDB/04462/2020 and UIDP/04462/2020 ) and the Associate Laboratory LS4FUTURE ( LA/P/0087/2020 ). The project was also funded by the European Union's European Innovation Council Transition program under grant agreement no. 101113067 . MSC was supported by FCT PhD fellowship 2022.12494.BD . Publisher Copyright: © 2025 International Society for Cell & Gene Therapy
Palavras-chave
controlled activation immunotherapy scalable manufacturing stirred-tank bioreactor T-cell phenotype Immunology and Allergy Immunology Oncology Genetics(clinical) Cell Biology Transplantation Cancer Research SDG 3 - Good Health and Well-being